Igniting the spark in six countries to transform the trajectory of postpartum hemorrhage across the globe: An overview of the AMPLI-PPHI project.

Postpartum hemorrhage (PPH) remains the leading cause of maternal mortality worldwide, disproportionately affecting women in low- and middle-income countries. Despite updated WHO recommendations and the availability of newer technologies-including heat-stable carbetocin, tranexamic acid as part of a clinical care bundle, misoprostol, and calibrated drapes-adoption and scale-up remain limited due to persistent supply and demand-side barriers. This article provides an overview of the Accelerating Measurable Progress and Leveraging Investments for Postpartum Hemorrhage Impact (AMPLI-PPHI) project. Led by Jhpiego, in partnership with PATH and FIGO, AMPLI-PPHI aims to reduce maternal mortality from PPH by catalyzing the adoption of effective drugs for PPH prevention and treatment as part of quality of intrapartum care, at all levels of the health system. Working in partnership with governments in project target countries (Democratic Republic of the Congo, Guinea, India, Kenya, Nigeria, and Zambia), AMPLI-PPHI helps to increase women's access to PPH prevention and management. AMPLI-PPHI introduces and integrates proven approaches and PPH commodities into routine maternal health systems, generates evidence, and supports countries in scaling up these practices. Globally, the project focuses on reducing supply-side barriers to help create the market for affordable and accessible PPH commodities. AMPLI-PPHI also fosters a regional exchange network-propelling shared learning and best practices-to light the spark for transformation in PPH care, thereby reducing maternal deaths from PPH-ensuring every woman, everywhere, has access to lifesaving care.